November 10, 2025 — Leads & Copy — Tivic Health Systems Inc. (Nasdaq: TIVC) is expanding its intellectual property (IP) portfolio with two new patent applications filed with the United States Patent and Trademark Office.
The first patent application relates to Tivic’s TLR5 agonist portfolio, which includes Entolimod and Entolasta. Titled “Immunomodulatory Pathway Modifying Agents and Uses of Same for Cancer Therapy,” the patent covers potential applications of TLR5 agonists, such as Entolimod and Entolasta, as an adjunctive therapy to improve the effectiveness of T-cell, NK-cell, and other immuno-oncology cell-based therapies for advanced-stage cancer.
According to the company, patients undergoing such therapies are often immunocompromised from earlier treatments. TLR5 agonists, used as an adjunctive therapy, may enhance the treatment outcomes.
The second patent application, “Vagus Nerve Electrical Stimulation System,” covers device parameters shown to have optimal impact on autonomic system activity via non-invasive vagus nerve stimulation.
Jennifer Ernst, CEO of Tivic, said the company is creating new potential partnership opportunities that can expand the market for its product candidates as it expands and protects its intellectual property rights. While Tivic’s commercial focus remains on advancing Entolimod toward a biologics license application for acute radiation syndrome, it would welcome opportunities to partner with other therapeutic companies whose products may benefit from enhanced immune activation, Ernst said.
Tivic’s dual platform uses the body’s biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Its biologic compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age.
Tivic’s lead drug candidate, Entolimod™, is a novel TLR5 agonist that has received Fast Track and Orphan Drug designations for acute radiation syndrome and is in late-stage development. The company also holds rights to develop Entolimod and its immunologically optimized derivative, Entolasta, for neutropenia.
Tivic’s bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways involved in many prevalent and debilitating diseases. Early trials showed promising signals that Tivic’s approach may regulate specific biologic responses and downregulate an overactive immune system. The company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices.
To learn more about Tivic, visit: https://ir.tivichealth.com.
Source: Tivic Health Systems, Inc.
